Chernett Jorey purchased $62K of STIM

Chernett Jorey purchased 35,000 shares of Neuronetics, Inc. (STIM) at $1.78 on 2026-07-14.

Original reporting
SEC EDGAR · Chernett Jorey
Published Jul 15, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Bullish
medium confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMBullishLow
01

Why it matters

A 10% owner purchased 35,000 shares at $1.7800, totaling $62,300, with holdings after the trade of 10,588,988 shares.

02

Market read

Traders may view the buy as a modest sentiment input, but there is no new operational or financial information.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide any 10b5-1 plan context (it says none), limiting inference about intent.

Relevance 4/10Novelty 3/10Timing: new Form 4 filed 2026-07-15, covering a 2026-07-14 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Neuronetics, Inc. (STIM).

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics insider Chernett Jorey, a 10% owner, bought 35,000 shares at $1.7800 on 2026-07-14 via open-market purchase.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat it as a confidence signal.

Evidence & confidence

Form 4 insider buys can influence sentiment, but this article provides no accompanying guidance, operational update, or material corporate event.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity and may not reflect near-term business improvement.

Key entities

  • Neuronetics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Chernett Jorey

    10% owner who executed an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.